Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Scorecards

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 95
3 125
2 34
1 19
Curative setting
A 38
C 2
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 28
Central Nervous System Malignancies 0
Endocrine Tumours 19
Gastrointestinal Cancers 53
Genitourinary Cancers 51
Gynaecological Malignancies 30
Head and neck cancer 6
Refractory NTRK fusion–positive cancers 2
Sarcoma 10
Skin Cancers 24
TMB-H solid tumours 1
Thoracic Malignancies 65
dMMR/MSI-H solid tumours 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 4
Gynaecological Malignancies 0
Head and neck cancer 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 8
TMB-H solid tumours 0
Thoracic Malignancies 2
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Evaluation form 1 For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    FOLFIRINOX - Gemcitabine 1st line advanced or metastatic. Good performance status Gastrointestinal Cancers Pancreatic cancer - -
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 2mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥1% KEYNOTE-010
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 10mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥1% KEYNOTE-010
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC >50% tumour cell PD-L1 expression Pembro 2mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥50% KEYNOTE-010
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>50% tumour cell PD-L1 expression Pembro 10mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥50% KEYNOTE-010
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Nivolumab - Docetaxel 2nd line after platinum-based therapy advanced squamous-cell NSCLC Thoracic Malignancies Non-small-cell Lung Cancer - Squamous cell - CheckMate 017
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Nivolumab - Docetaxel 2nd line after platinum-based therapy advanced non-squamous-cell NSCLC stratified for PD-L1 Thoracic Malignancies Non-small-cell Lung Cancer - CheckMate 057
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pembrolizumab - Platinum-based chemotherapy 1st line metastatic and advanced NSCLC with PD-L1>50% Thoracic Malignancies Non-small-cell Lung Cancer - KEYNOTE-24
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Dab/Tram (dabrafenib and trametinib) - Vemurafenib 1st line unresectable or metastatic melanoma with the BRAF V600E mutation Skin Cancers Melanoma BRAF V600E COMBI-v
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Radium-223 Best standard of care Best standard of care + placebo Late line and bone pain, castration-refractory, late line and bone pain Genitourinary Cancers Prostate cancer - ALSYMPCA
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.